Literature DB >> 8918945

Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice.

K Takashima1, K Tateda, T Matsumoto, T Ito, Y Iizawa, M Nakao, K Yamaguchi.   

Abstract

Examination of strain differences in the susceptibility of mice to experimental respiratory tract infection with penicillin-resistant Streptococcus pneumoniae TUM19 revealed that a fatal infection model could be induced in immunocompetent CBA/J mice, but not in C3H/HeN, C57BL/6 or ICR mice. After intranasal instillation of c. 10(6) cfu of S. pneumoniae, the bacterial counts in the lungs of CBA/J mice increased from 10(5) to 10(7) cfu after 3-5 days, and gradually increased thereafter. The challenge organisms localised mainly in the lungs until 14 days after infection. Mice began to die c. 7 days after infection, and by 3 weeks most of the mice had died. Histopathologically, infiltration of neutrophils and lymphocytes around bronchi was observed from 1 day after infection, and fibrin deposition was seen in alveolar and bronchial spaces from 5 days. This model may be useful for investigating therapy of respiratory tract infection caused by penicillin-resistant S. pneumoniae because its pathological features resemble those observed in the human disease.

Entities:  

Mesh:

Year:  1996        PMID: 8918945     DOI: 10.1099/00222615-45-5-319

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  11 in total

Review 1.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

3.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains.

Authors:  N A Gingles; J E Alexander; A Kadioglu; P W Andrew; A Kerr; T J Mitchell; E Hopes; P Denny; S Brown; H B Jones; S Little; G C Booth; W L McPheat
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.

Authors:  K Yamaguchi; H Domon; S Miyazaki; K Tateda; A Ohno; K Ishii; T Matsumoto; N Furuya
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice.

Authors:  K Takashima; K Tateda; T Matsumoto; Y Iizawa; M Nakao; K Yamaguchi
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

7.  In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.

Authors:  Yoshiko Otsu; Katsunori Yanagihara; Yuichi Fukuda; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Jun-ichi Kadota; Takayoshi Tashiro; Ikuo Murata; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Susceptibility to progressive Cryptococcus neoformans pulmonary infection is regulated by loci on mouse chromosomes 1 and 9.

Authors:  Scott F Carroll; Erin I Lafferty; Adam Flaczyk; T Mary Fujiwara; Robert Homer; Kenneth Morgan; J C Loredo-Osti; Salman T Qureshi
Journal:  Infect Immun       Date:  2012-09-17       Impact factor: 3.441

Review 9.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

10.  In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic.

Authors:  S Tamura; S Miyazaki; K Tateda; A Ohno; Y Ishii; T Matsumoto; N Furuya; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.